DotBio is developing an internal pipeline of innovative, multi-functional antibody therapies to treat and cure cancer. (Currently undisclosed)
Out-licensing and Partnering opportunities
DotBio’s platform is open for out-licensing and partnerships. We are looking to partner with pharmaceutical companies under different modalities. These include:
Co-development projects based on DotBio’s current bank of DotBody modules or new DotBody modules generated through the partnership
Out-licensing deals involving DotBody modules to attach to existing monoclonal antibodies
Out-licensing deals involving drug candidates in DotBio’s pipeline